Safety assessment of essential medicines for elderly people: a bibliographic survey by Varallo, Fabiana Rossi et al.
Correspondence: P. C. Mastroianni. Faculdade de Ciências Farmacêuticas, 
Universidade Estadual Paulista “Júlio de Mesquita Filho”. Rodovia Araraquara - 
Jaú, km 1, 14801-902 - Araraquara - SP, Brasil. E-mail: pmastro@fcfar.unesp.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 50, n. 2, apr./jun., 2014
http://dx.doi.org/10.1590/S1984-82502014000200006
Safety assessment of essential medicines for elderly people: a 
bibliographic survey
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Certain medicines are considered potentially inappropriate (PIM) for elderly people as they increase the 
risk of adverse drug events (ADE) and because safer alternative therapies are available on the market. 
In this context, in order to identify the instruments that assess the quality of medical prescriptions for 
elderly and to determine which drugs are considered PIM, a bibliographic survey was conducted in 
PUBMED, LILACS and PAHO databases, in February and March/2010. The search strategy included 
the use of health descriptors and a manual search in the references cited by selected papers. During the 
period of data collection, 15 instruments were identified. In 2012, with the publication of the update of 
Beers criteria, this instrument was included in the study. We identified 163 PIM of 25 therapeutic classes, 
of which 125 (76.7%) are marketed in Brazil. Of these, 31 (24.8%) are essential medicines (RENAME 
2012), of which 13 have safer therapeutic equivalents and 19 (15.2%) are over-the-counter drugs. Data 
suggest the need for inclusion of safer alternatives for the elderly in the national list of essential medicines 
and the pharmaceutical care for early detection of ADE in this age group, in order to contribute to the 
safe use of medicines.
Uniterms: Aged/medicines prescription. Medication/errors. Medicines/inappropriate prescribing. 
Medicines/adverse effects/control. Medicines/safety use. Medication/risk assessment/control. 
Pharmaceutical care.
Determinados medicamentos são considerados potencialmente inapropriados (MPI) para idosos, por 
aumentarem o risco de ocorrência de eventos adversos a medicamentos (EAM) e por existirem alternativas 
terapêuticas mais seguras. Neste contexto, com o intuito de identificar os instrumentos que avaliam a 
qualidade das prescrições médicas para idosos e verificar quais medicamentos são considerados MPI, 
levantamento bibliográfico foi realizado nas bases de dados PUBMED, LILACS e PAHO em fevereiro 
e março de 2010. Para a seleção dos manuscritos utilizaram-se descritores em saúde e busca manual nas 
referências bibliográficas dos artigos identificados. No período da coleta de dados, foram identificados 
15 instrumentos. Em 2012, com a publicação da atualização da lista de Beers, este instrumento foi 
incluído no estudo. Foram identificados 163 MPI de 25 classes terapêuticas, dos quais 125 (76,7%) são 
comercializados no Brasil. Destes, 31 (24,8%) são medicamentos essenciais (RENAME 2012), sendo 
que para 13 deles há equivalentes terapêuticos mais seguros e 19 (15,2%) são medicamentos isentos 
de prescrição. Os dados sugerem a necessidade de inclusão de medicamentos mais seguros para idosos 
na lista nacional de medicamentos essenciais e do monitoramento farmacoterapêutico para a detecção 
precoce de EAM nesta faixa etária para contribuir com o uso seguro de medicamentos.
Unitermos: Idoso/prescrição de medicamentos. Medicação/erros. Medicamentos/prescrição inadequada. 
Medicamentos/efeitos adversos/controle. Medicamentos/uso seguro. Medicação de risco/controle. 
Monitoramento farmacoterapêutico.
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INTRODUCTION
Population aging is a worldwide phenomenon. 
However, this process is occurring evenly over all 
countries. In 2050, 80% of all elderly people will be 
distributed among the developing nations (WHO, 2004). 
Thus, the United Nations Initiative (UNS, 1999) suggested 
that all countries should prepare their health care systems, 
as well as economic planning and social services in order 
to meet the needs of the elderly population.
In particular, the development of public health policies 
have to be developed for the elderly, in order to provide 
them with quality health care. In Brazil, the main laws are: 
the National Health Policy for the Elderly (Brasil, 1994), 
which aims “to promote healthy aging, with maintenance 
and improvement of their health condition, [...] functional 
capacity, and the prevention of disease and restoration of 
the health”; the Statute of Elderly People (Brasil, 2003), 
which ensures the comprehensive health care for the elderly, 
provided by the National Health Service (SUS), ensuring 
universal and equal access in an integrated and continuous 
set of actions and services for the prevention, promotion, 
protection and restoration of health.
Brazil is in a process of demographic transition, 
in which a marked aging of the population is evident. 
According to IBGE (2013), 33.7% of population will 
be more than 60 years old by 2060. Consequently, there 
is also an epidemiological transition, with important 
changes in the morbidity and mortality rates (IBGE, 
2009), since the country will have changed the mortality 
profile until recently typical of young citizens, for a profile 
characteristic of senescence, with more complex and 
costly diseases (Gordilho et al., 2000).
Elderly patients who have complex medical 
problems and use polypharmacy (taking five or more 
drugs) are particularly more likely to be affected by 
medication errors (Fiolavá, Onder, 2009), such as the 
prescription of potentially inappropriate medications 
(PIM), and to be hospitalized (De Paula et al., 2012). 
Moreover, the inherent physiological changes of the 
aging process may influence the pharmacokinetics 
and pharmacodynamics of a drug, resulting in greater 
sensitivity to both its therapeutic and adverse effects 
(Corsonello et al., 2010).
PIM are those medications or classes of medication 
that should be avoided in patients aged ≥ 65 years, since 
they have no clear evidence-based efficacy, are not cost-
effective (Beers et al., 1991) and on pose unnecessary 
risk to the health of the elderly, in that the risks of using 
those drugs exceed the benefits and safer alternatives are 
available (Fick et al., 2003; Gallagher et al., 2008).
One way to assess the quality of drug prescriptions 
for elderly patients is to use instruments that incorporate 
explicit (Bongue et al., 2009) and implicit indicators. The 
former list the drugs considered inappropriate for this age 
group and the latter consider the pathophysiology of the 
patient and the use of concomitant medications. However, 
these instruments are only tools that can guide drug 
prescription (Smet et al., 2007; Spinewine et al., 2007; 
Castelino et al., 2009) and must not replace clinical and 
pharmacotherapeutic assessment for the selection of the 
most appropriate drug in order to obtain the best results 
(Castelino et al., 2009).
Several criteria that evaluate the safety of pharmaco-
therapy for elderly people have been published, however 
no one criteria is established as a gold standard. Therefore, 
the aim of this study was to: 1) identify the instruments 
developed to assess the safety of pharmacotherapy 
for elderly people; 2) determine the drugs considered 
potentially inappropriate for this age group, according to the 
instruments identified, and 3) identify the PIM contained 
in the Brazilian list of essential drugs (RENAME), in order 
to propose safer therapeutic equivalents for elderly people.
METHODS
During February and March of 2010, a bibliographic 
survey was performed in Pubmed, LILACS and PAHO 
databases (available at http://regional.bvsalud.org/php/
index.php), in order to identify the original studies that 
developed or used instruments to analyze the quality of 
drug prescriptions for elderly people (aged ≥ 65 years). 
The search strategy adopted the following scientific 
health descriptors: “drug prescription” AND “aged” 
OR “elderly people” AND “medication errors”, as well 
as the key words: “screening tool” AND “inappropriate 
medications”. Other relevant publications were localized 
by a manual search, consulting the references of selected 
articles.
Original studies published in journals indexed in the 
databases consulted, which were written in the English, 
Portuguese or Spanish languages and developed and/
or applied instruments that contained implicit or explicit 
indicators for quality analysis of drug prescription for elderly 
people were considered eligible for the present review. The 
exclusion criteria comprised: review manuscripts, editorials, 
letters, news, abstracts of conference proceedings and data 
from thesis and dissertations.
The articles were independently selected by two 
reviewers, using the techniques of floating reading and 
content analysis. The first allowed the pre-selection of 
primary studies whose titles and abstracts referred to the 
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theme of the study. Each pre-selected study was assessed 
by the technique of content analysis, in order to verify that 
it matched the inclusion criteria previously established 
and to identify the drugs considered inappropriate for use 
in senescence.
The drugs classified as PIM by the instruments 
identified were analyzed, in order to determine whether 
they are present in the 16th WHO Model List of Essential 
Medicines (WHO, 2010) and in the List of Essential 
Medicines in Brazil (RENAME, 2010) (Brasil, 2010). For 
those included in the criteria of essential medicines (PIM 
present in WHO and RENAME lists), safer equivalent 
therapies were suggested, where possible, on the basis of 
articles consulted and the pharmacological characteristics 
of the drugs. 
Since the implicit criteria require clinical evaluation 
of patient and of the drugs taken, the instruments 
using these indications do not list the PIM for the 
elderly population, since any drug could be considered 
inappropriate. For this reason, they were not considered 
for data tabulation.
RESULTS
By the search strategy proposed, 203 articles were 
identified. Of these, 156 satisfied the exclusion criteria 
and 47 had their content analyzed. After content analysis, 
12 of these articles were excluded, since they did not 
refer to the instruments used to evaluate the safety of 
pharmacotherapy for elderly people. After this process, 
34 articles were considered eligible for the study.
Fifteen instruments to assess the quality of drug 
prescriptions for elderly people were identified: the Beers 
criteria (1991) (Beers et al., 1991) and their updates in 
1997 (Beers, M.H.; 1997), 2003 (Fick et al., 2003), the 
Medication Appropriateness Index (MAI) (Hanlon et 
al., 1992), the Lipton (Lipton et al., 1993) and McLeod 
(McLeod et al., 1997) criteria, the HEDIS method (Pugh 
et al., 2006), Norwegian quality indicators for prescribing 
(Brekke et al., 2008), Swedish quality indicators of 
prescription (Johnell, Fastbom, 2008), the Improving 
Prescribing in the Elderly Tool (Ipet) (Naugler et al., 
2000), the French list of inappropriate drugs (Laroche 
et al., 2007), the Norwegian list of inappropriate drugs 
(Straand, Rokstad, 1999), the Screening Tool to Alert 
doctors to the Right Treatment (START) (Barry et al., 
2007), Zhan criteria (Zhan et al., 2001), and the Screening 
Tool of Older Persons’ Potentially Inappropriate 
Prescriptions (STOPP) (Gallagher, O’Mahony, 2008). In 
2012, a new version of the Beers criteria (AGS, 2012) was 
published. Therefore, in order to update our findings, this 
instrument was included in our revision. Thus, we found 
16 instruments.
Of these instruments, the MAI (Hanlon et al., 1992) 
and the Lipton criteria (Lipton et al., 1993) incorporate 
implicit indicators for the assessment of the quality of 
prescriptions for the elderly. 
The instruments STOPP (Screening Tool of Older 
Persons’ Prescriptions) and START (Screening Tool to 
Alert doctors to the Right Treatment) (Gallagher et al., 
2008) list 8 therapeutic classes of potentially inappropriate 
medications for the elderly.
Eleven instruments (Beers et al., 1991; Beers, 1997; 
Straand, Rokstad, 1999; Naugler et al., 2000; Zhan et 
al., 2001; Fick et al., 2003; Pugh et al., 2006; Laroche et 
al., 2007; Brekke et al., 2008; Johnell, Fastbom, 2008; 
AGS, 2012) considered 163 drugs of 25 therapeutic 
classes PIM for elderly people, which should be avoided, 
irrespective of the diagnosis or conditions of the patient 
(Table I). According to WHO the Anatomical Therapeutic 
Chemical (ATC) Classification system, 33.1% (54/163) 
of PIM act on the nervous system, 16.5% (27/163) on the 
cardiovascular system, 6.7% (11/163) on the respiratory 
system, 10.4% (17/163) on the musculoskeletal system, 
8.6% (14/163) on the alimentary tract and metabolism, 
3.7% (6/163) on genitourinary system and sex hormones, 
and 1.8% (3/163) on blood and hematopoietic organs, 
while 0.6% (1/163) are systemic hormones and 0.6% 
(1/163) are anti-infective. Another 18 drugs found were 
classified as acting on 2 or more ATC therapeutic classes, 
while 14 drugs were not found in this classification.
The 2012 updating of Beers criteria (AGS, 2012) 
covers 72.4% of all PIM identified in the assessed studies, 
followed by the 2003 updating of Beers criteria (Fick et 
al., 2003) and by the list developed in France (Laroche et 
al., 2007) (Table II).
Finally, it was observed that 19 PIM are present in 
the 16th WHO Model List of Essential Medicines (WHO, 
2010) and 20 (5.8%) in the RENAME 2010 (Table III). 
Thus, these drugs are considered essential, according 
to the criteria of cost, safety, quality and effectiveness. 
Regarding the proposal of safer equivalent therapies, seven 
PIM classified as essential medicines in the Rename list 
have no safer equivalents (Table III). When we examined 
the PIM classified as essential drugs in the WHO list, in 
eight cases it was not possible to propose safer equivalent 
therapies for elderly people (Table III).
In 2012, there was an update of the RENAME list, 
which now includes 31 PIM (acetylsalicylic acid, cáscara 
sagrada, chlorpromazine, fluoxetine, metoclopramide, 
promethazine, clobazam, clonazepam, amiodarone, 
amitriptyline, clomipramine, propaphenone, propranolol, 
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TABLE I - List of potentially inappropriate medications (PIM) for the elderly that should be avoided irrespective of diagnosis or 
clinical condition, according to the methods identified in PAHO (available in: http://regional.bvsalud.org/php/index.php), Lilacs 
and Pubmed databases, during the period between February and March 2010 (n=12)
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Ethacrynic  acid (C03CC01) X
Analgesics X
Salicylic acid (>325mg/d)(N02BA01) X
   Diclofenac (M01AB05) X
   Diflunisal (N02BG) X
   Etodolac (M01AB08) X
   Fenoprofen (M01AE04) X
   Ibuprofen (M01AE01) X
   Indometacin (M01AB01) X X X X X X X
   Ketoprofen (M01AE03) X
   Ketorolac (M01AB15) X X X
   Mefenamic acid (M01AG01) X
   Meloxicam (M01AC06) X
   Nabumetone (M01AX01) X
   Naproxen (M01AE02) X X
   Oxaprozin (M01AE12) X X
   Phenylbutazone (M01AA01) X X X
   Piroxicam (M01AC01) X X
   Sulindac (M01AB02) X
   Tolmetin (M01AB03) X
Antiparkinson agents
   Benzatropine (N04AC01) X
  Trihexyphenidyl (N04AA01) X
Antispasmodic X
  Belladonna alkaloids (A03BA) X X X X X
   Clidinium-chlordiazepoxide (A033CA02) X X X X
   Dicyclomine (A03AA07) X X X X X
   Hyoscyamine (A03BA03) X X X X X
   Propantheline (A03AB05) X X X X
   Oxybutynin (G04BD04) X X X X X
   Scopolamine (A04AD01) X
Anti-emetics
   Trimethobenzamide (none) X X X X X
Amphetamines and anorexic oral anti-infectives X X
   Nitrofurantoin (J01XE01) X X X X X
Anticholinergics X X
Antidepressants X
   Amitriptyline (N06AA09) X X X X X X X X X
   Amoxapine (N06AA17) X
   Clomipramine (N06AA04) X X X
   Doxepin (N06AA12) X X X X X X X
   Fluoxetine (N06AB03) X
   Imipramine (N06AA02) X X X
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TABLE I - List of potentially inappropriate medications (PIM) for the elderly that should be avoided irrespective of diagnosis or 
clinical condition, according to the methods identified in PAHO (available in: http://regional.bvsalud.org/php/index.php), Lilacs 
and Pubmed databases, during the period between February and March 2010 (n=12) (cont.)
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   Maprotiline (N06AA21) X
   Trimipramine (N06AA06) X X X
Oral antidiabetics
   Carbutamide (A10BB06) X
   Chlorpropamide (A10BB02) X X X X X X X X
   Glipizide (A10BB07) X
   Glibenclamide (A10BB01) X
Antihistamines X
   Alimemazine (R06AD01) X X
   Brompheniramine (R06AB01) X X
   Carbinoxamine (R06AA08) X X
   Cimetidine (A02BA01) X X X
   Clemastine (R06AA04) X
   Cyproheptadine (R06AX02) X X X X X X
   Chlorpheniramine (R06AB02) X X X X X
   Dexbrompheniramine(R06AB06) X
   Dexchlorpheniramine(R06AB02) X X X X X X
   Diphenhydramine (R06AA02) X X X X X
   Doxylamine (R06AA09) X X
   Hydroxyzine (N05BB01) X X X X X X X
   Promethazine (R06AD02) X X X X X X X
   Tripelennamine (R06AC04) X X X
   Triprolidine (R06AX07) X
Antiplatelet
   Dipyridamole (B01AC07) X X X X X X X X
   Ticlopidine (B01AC05) X X X X X
Antipsychotics X
   Cyamemazine (N05AA06) X
   Chlorpromazine (N05AA01) X X
   Chlorprothixene (N05AF03) X
   Fluphenazine (N05AB02) X
   Haloperidol (N05AD01) X X X
   Levomepromazine (N05AA02) X X
   Mesoridazine (N05AC03)  X X X
   Perphenazine (N05AB03) X
   Pipotiazine (N05AC04) X
   Prochlorperazine (N05AB04) X
   Pericyazine (N05AC01) X
   Thioridazine (N05AC02) X X X X
Cardiovascular X
   Amiodarone (C01BD01) X X
   Clonidine (C02AC01) X X X
   Digoxin (C01AA05) X X X X
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   Disopyramide (C01BA03) X X X X X
   Dofetilide (C01BD04) X
   Doxazosin (C02CA04) X X
   Dronedarone (C01BD07) X
   Flecainide (C01BC04) X
   Guanabenz (none)
   Guanadrel (none)
   Guanfacine (C02AC02)
   Guanethidine (C02CC02)
   Hydrochlorothiazide (C03AA03) X X
X
X
X
X
X
X
X
   Ibutilide (C01BD05) X
   Methyldopa (C02AB) X X X X X X X
   Moxonidine (C02AC05) X
   Nifedipine (C08CA05) X X X X
   Nicardipine (C08CA04) X
   Prazosin (C02CA01) X
   Procainamide (C01BA02) X
   Propafenone (C01BC03) X
   Propranolol (C07AA05) X X
   Quinidine (C01BA01) X
   Reserpine (C02AA02) X X X X X X
   Rilmenidine (C02AC06) X
   Sotalol (C07AA07)
   Spironolactone (C03DA01)
X
X
   Terazosin (G04CA03) X
Ergot derivatives (C04AE) X X
Descongestants
   Phenylephrine (R01AA04) X
   Pseudoephedrine (R01BA02) X
   Oxymetazoline (R01AA05) X
Hypnoanalgesics 
   Meperidine (N02AB02) X X X X X
   Pentazocine (N02AD01) X X X X X X
   Pethidine (N02AB02) X
   Propoxyphene (N02AC04) X X X X X X X
Hypnotics/sedatives X
Barbiturates X X
   Amobarbital (N05CA02) X
   Butabarbital (none) X
   Butalbital (none) X
   Mephobarbital (N03AA01) X
   Pentobarbital (N05CA01) X X X X
   Phenobarbital (N03AA02) X
TABLE I - List of potentially inappropriate medications (PIM) for the elderly that should be avoided irrespective of diagnosis or 
clinical condition, according to the methods identified in PAHO (available in: http://regional.bvsalud.org/php/index.php), Lilacs 
and Pubmed databases, during the period between February and March 2010 (n=12) (cont.)
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TABLE I - List of potentially inappropriate medications (PIM) for the elderly that should be avoided irrespective of diagnosis or 
clinical condition, according to the methods identified in PAHO (available in: http://regional.bvsalud.org/php/index.php), Lilacs 
and Pubmed databases, during the period between February and March 2010 (n=12) (cont.)
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   Secobarbital (N05CA06) X X X X
Benzodiazepines
  Long-term X X
   Bromazepam (N05BA08) X
   Chlordiazepoxide (N05BA02) X X X X X X X
   Clobazam (N05BA09) X
   Clonazepam (N03AE01) X
   Clorazepate (N05BA05) X X X X
   Diazepam (N05BA01) X X X X X X X
   Flurazepam (N05CD01)
   Flunitrazepam (N05CD03)
   Halazepam (N05BA13)
X X X
X
X X
X
X
X
   Loflazepate (N05BA18) X 
   Nitrazepam (N05CD02) X X X
   Nordazepam (N05BA16) X
   Quazepam (N05CD10) X X X
   Prazepam (N05BA11) X
   Tetrazepam (M03BX07) X
 Short term
   Alprazolam (N05BA12) X X X X
   Estazolam (N05CD04) X X
   Eszopiclone (N05CF04) X
   Lorazepam (N05BA06) X X X
   Oxazepam (N05BA04) X X X X
   Temazepam (N05CD07) X X X
   Triazolam (N05CD05) X X X X
   Zaleplon (N05CF03)
   Zolpidem (N05CF02)
Meprobamate (N05BC01) X
X
X X X
X
X
X
Endocrine
 Androgens (G03B)
X
   Methyltestosterone (G03BA02)
   Testosterone (G03BA03)
X X X
X
  Desiccated thyroid (H03)
  Estrogen (G03C)
X
X
X
X
X
X
  Growth hormone (L03) X
  Insulin, sliding scale (A10AB) X
  Megestrol (G03AC05) X
Gastrointestinal/ laxatives X
   Bisacodyl (A06AB02) X X
   Cáscara Sagrada (A06AB07) X X
   Metoclopramide (A03FA01) X
   Mineral oil (A06AA) X X X
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   Castor oil (A06AB05) X X
   Ranitidine (A02BA02) X
Muscle relaxants X
   Baclofen (M03BX01) X
   Carisoprodol (M03BA02) X X X X X X X
   Cyclobenzaprine (M03BX08) X X X X X X
   Chlorzoxazone (M03BB03) X X X X X
   Metaxalone (none) X X X X X
   Methocarbamol (M03BA03) X X X X X X X
   Orphenadrine (M03BC01) X X X X
   Solifenacin (G04BD08) X
   Tolterodine (G04BD07) X
Ferrous sulphate (B03AA07) X X X
Theophylline (R03DA04) X
Treatments for dementia
   Cyclandelate (C04AX01) X X X X
   Isoxsuprine (C04AA01) X  X    X    X
TABLE I - List of potentially inappropriate medications (PIM) for the elderly that should be avoided irrespective of diagnosis or 
clinical condition, according to the methods identified in PAHO (available in: http://regional.bvsalud.org/php/index.php), Lilacs 
and Pubmed databases, during the period between February and March 2010 (n=12) (cont.)
TABLE II - Frequency of drugs considered potentially 
inappropriate medications (PIM) for elderly people, according to 
the instruments identified in Paho, Lilacs and Pubmed databases 
in February and March 2010, whose use should be avoided 
irrespective of the diagnosis or conditions of the patient
Instruments PIM - N (%)
Beers (2012) 118 (72.4)
Fick DM, et al. (2003) 73 (44.7)
Laroche ML, et al. (2007) 61 (37.4)
Beers MH, et al. (1997) 49 (30.0)
Pugh MJV, et al. (2006) 44 (26.9)
Beers MH. (1991) 38 (23.3)
Zhan C, et al. (2001) 33 (20.2)
Breeke M, et al. (2008) 19 (11.6)
Johnell K,  et al. (2008) 10 (6.1)
Straand J, et al. (1999) 9 (5.5)
Naugler CT, et al. (2000) 4 (2.4)
Total of PIM 163 (100.0%)
ranitidine, spironolactone, estrogens, diazepam, digoxin, 
phenobarbital, haloperidol, hydrochlorothiazide, 
ibuprofen, insulin, dexchlorpheniramine, nifedipine, 
nitrofurantoin, doxazosin, methyldopa, mineral oil, ferrous 
sulphate, trihexyphenidyl). In this update, the only PIM 
that was removed from the list was testosterone. However, 
testosterone was maintained in the 17th WHO Model List 
of Essential Medicines.
Moreover, among the 16 criteria identified, only 
eleven listed the drugs that should be avoided on the basis 
of diagnosis or the conditions of patient (drug interaction 
with the disease), the co-prescriptions that should be 
avoided in senescence and drugs for which is necessary 
to pay attention to the dose, duration and frequency of the 
treatment (Table III).
DISCUSSION
The pharmacotherapy prescribed, especially for 
the elderly population, should be effective and avoid 
potentially harmful drugs, since most of the adverse 
drug events appear in the post-commercialization period. 
Topinková et al. (2012) showed that strategies have been 
developed to target these goals which are focused on drug 
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TABLE III - Potentially inappropriate medications (PIM) for elderly people listed by the instruments identified in Paho, Lilacs and 
Pubmed databases, during Februrary and March 2010, which are present in the Brazilian list of essential medicines (RENAME 
2010) and in the 16th WHO Model List of Essential Drugs, and their possible equivalent therapies.
RENAME 2010 WHO MODEL LIST
PIM Therapeutic equivalent proposed
The therapeutic 
equivalent is listed 
in Rename 2010?
PIM  Therapeutic equivalent
The therapeutic 
equivalent is in 
WHO model list?
amiodarone verapamil yes amidarone verapamil yes
amitriptyline sertraline no amitriptilyne sertraline no
clomipramine sertraline no clorfenidramina loratadine no
clonazepam * short-acting 
benzodiazepine
no clomipramine sertraline no
chlorpromazine quetiapine yes chlorpromazine quetiapine no
diazepam * short-acting 
benzodiazepine
no diazepam * short-acting 
benzodiazepine
yes
digoxin - - digoxin - -
dexclorfenidramine loratadine yes fluoxetine sertraline no
estrogen - - haloperidol             -
fluoxetine sertraline no hydrochlorothiazide - -
haloperidol - - lorazepam -
hydrochlorothiazide - - methyldopa losartan no
methyldopa losartan yes nifedipine - yes
ciprionate 
testosterone
- - nitrofurantoin ciprofloxacin yes
nifedipine - yes promethazine loratadine no
nitrofurantoin ciprofloxacin yes propranolol - -
promethazine loratadine yes ranitidine omeprazole yes
propranolol atenolol yes ferrous sulphate - -
ranitidine omeprazole yes testosterone - -
ferrous sulphate - -
*The dose in the elderly should be half or less than half the dose recommended for a young adult <27>.
appropriateness, adherence and adverse drug events. The 
authors highlight the medication review as one of the 
more promising interventions to assess the risk/benefit of 
geriatric pharmacotherapy. To promote this kind of safety 
assessment, our study identified the instruments that may 
be applied to assess the quality of medical prescription 
for elderly people.
However, since the criteria were developed in 
North America (Beers criteria and their updates) and 
Europe, there is a need to adapt an instrument of PIM 
classification to Brazilian conditions (Ribeiro et al., 2005), 
since 23% (38/165) of inappropriate geriatric medicines 
are not marketed in Brazil (ethacrynic acid, alimemazine, 
amobarbital, amoxapine, butalbital, carbutamide, 
cyamemazine, cyclandelate, clidinium-chlordiazepoxide, 
chlorprothixen, diflunisal, eszopiclone, guanabenz, 
guanadrel, guanfacine, guanethidine, halazepam, 
loflazepate, meprobamate, mesoridazine, metaxalone, 
methocarbamol, nicardipine, nordazepam, oxaprozin, 
pentazocine, perphenazine, prazepam, procainamide, 
prochlorperazine, propantheline, quazepam,  secobarbital, 
temazepam, tetrazepam, tolmetin, trimethobenzamide, 
trimipramine). A review carried out by Corsonello et al. 
(2012) corroborates this argument. The authors noted that 
the START/STOPP criteria were developed to promote 
the prevention of inappropriate prescribing in European 
nations, since the 2003 updated Beers criteria include 
drugs that are not available in Europe or hardly ever are 
prescribed. Therefore, with the aid of Brazilian criteria, 
the prevalence of appropriate pharmacotherapy may be 
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TABLE IV - List of potentially inappropriate medications (PIM) for the elderly that should be avoided as indicated by the clinical 
diagnosis of the patient (drug interaction with disease), the dose, frequency and duration of the drug administration and drug 
association, according to the methods identified in PAHO (available at: http://regional.bvsalud.org/php/index.php), Lilacs and 
Pubmed databases, during the period between February and March 2010 (n=10)
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Combinations
NSAIDs + Diuretics X
NSAIDS + Meperidine ou Pentazocine X
NSAIDS + Piroxicam, Ketorola or Mefenamic acid X
NSAIDS + ACEi X
NSAIDS + SSRI X
NSAIDS + Warfarin X X X
Amitriptyline + Chlordiazepoxide X X X
Amitriptyline + Perphenazine X X X X
Anticholinergic + Antipsychotics X X
Cimetidine + Warfarin X
Clidinium + Chlordiazepoxide X X
Corazepato + Acepromazine X
Desclorfeniramina + Betamethasone X
SSRI + MAOI X
Methyldopa + Hydrochlorothiazide X X
Dose limits, frequency and duration of treatment
Acetylsalicylic acid   ≥150mg/dia (dose) X
Pain relievers containing codeine X
Antibiotics prescribed for the first crisis of bronchitis X
Gastrointestinal antispasmodics X
1st generation antihistamines (duration) X
Antipsychotic drugs (dose, duration) X X
Antipsychotics for nonpsychotic diagnoses X
Barbiturates (duration) X
Benzodiazepines (dose, duration) X X X X
H2 blockers (dose. frequency and duration) X
Decongestants (duration) X
Digoxin (dose) X
Iron supplements (dose and frequency) X
Thiazides (dose) X X
Three or more psychotropic drugs (duration) X
Interaction Pathology
Adenoma of the prostate, glaucoma and urinary retention X 
anticholinergic X
Angina in patients with a history of asthma, COPD or heart 
failure X β-blockers X
Anorexia and malnutrition X central nervous system stimulants X
Conductive cardiac abnormalities X tricyclic antidepressant X
Arrhythmias X tricyclic antidepressants X
No history of coronary symptoms, cerebral or peripheral vascular 
occlusive or event X Acetylsalicylic acid X
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Chronic constipation without concomitant use of laxatives X 
opioids for more than 2 weeks X
Constipation X tricyclic antidepressant X
Seizures X clozapine, chlorpromazine, thioridazine and 
thiothixene X
Dementia X anticholinergics, trihexafenidil, tropatepina, 
biperiden, neuroleptics (except risperidone and olanzapine) and 
benzodiazepines
X
Depression X active metabolites with tricyclic antidepressant 
(eg amitriptyline or imipramine) X
Depression X long-acting benzodiazepines and sympatholytic 
agents X
Depression X methylphenidate X X
Clotting disorders X NSAIDs, dipyridamole, ticlopidine and 
clopidogrel X
Diabetes mellitus and frequent hypoglycemia X β-blockers X
Diabetes X corticoids X
Diarrhea or gastroenteritis of unknown cause severe X 
diphenoxylate, loperamide or codeine X X X
Parkinson’s Disease X Metoclopramide, conventional 
antipsychotics, tacrine X
Raynaud’s DiseaseX prolonged use of β-adrenergic blocker X
Moderate pain X long-term use of potent opioids as a first 
treatment option X
COPD X beta blockers and benzodiazepines long-term X X X X
COPD X theophylline X
Muscle spasms X cyclobenzaprine or methocarbamol X
Stress X benzodiazepínios beta-blockers and long acting X
Atrial fibrillation X disopyramide X
Drop X thiazide diuretic X X X
Drop X indomethacin X
Benign prostatic hyperplasia, glaucoma or cardiac arrest X 
tricyclic antidepressant X X
Moderate to severe hypertension X NSAIDS X X X
Hypertension X phenylpropanolamine, pseudoephedrine and 
amphetamines X
Hypertension X reserpine X
Postural hypotension X tricyclic antidepressants X
Postural hypotension X chlorpromazine X
Urinary incontinence X urapidil and prazosin X
Insomnia X decongestants, theophylline, methylphenidate, 
MAOI, amphetamine X
TABLE IV - List of potentially inappropriate medications (PIM) for the elderly that should be avoided as indicated by the clinical 
diagnosis of the patient (drug interaction with disease), the dose, frequency and duration of the drug administration and drug 
association, according to the methods identified in PAHO (available at: http://regional.bvsalud.org/php/index.php), Lilacs and 
Pubmed databases, during the period between February and March 2010 (n=9) (cont.)
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Insomnia X prolonged use of triazolam X
Heart failure X NSAIDS X X
Heart failure X  β-adrenergic blocker X X
Heart failure X Calcium channel blockers X X X
Heart failure X drugscom disopyramide and high sodium X X
Chronic renal failure X NSAIDS X X
Obesity X olanzapine X
Chronic constipation X calcium channel blockers, 
anticholinergics, and tricyclic antidepressants X X
Chronic osteoarthritis X phenylbutazone X
Moderate osteoarthritis X NSAIDS X X X
Osteoarthritis or rheumatoid arthritis X long-term corticosteroids X
Parkinson X long-term neuroleptic X
Cognitive impairment X anticholinergic or antispasmodic X
Cognitive impairment X tricyclic antidepressant X
Cognitive impairment X antimuscarinic X
Cognitive impairment X barbiturates, anticholinergics, 
antispasmodics, muscle relaxants and CNS  stimulants
X
Cognitive impairment X  niacin or pentoxifylline X
Cognitive impairment X Prolonged use of opioids X
Renal damage X digoxin > 0,125 mg/dia X
Prevention of myocardial X dipyridamole X X
Chronic prostatism X antimuscarinic X
Prostatism or history of urinary retention X tricyclic 
antidepressant X
Urinary retention X anticholinergics, antihistamines, GI 
antispasmodics, muscle relaxants, oxybutynin, flavoxate, 
antidepressants, and tolterodine 
X
Syncope or falls X short-acting benzodiazepines or tricyclic 
antidepressants or intermediate X
Syndrome of inappropriate secretion of the hormone antidiuretic 
/ hyponatremia X SSRI X
Tendency to fall X benzodiazepines, neuroleptics, vasodilators 
and long-term opioid X
Maintenance therapy of moderate to severe COPD X corticoids X
Dizziness X bupropion X
Treatment of gout when there is no contraindication to 
allopurinol X prolonged use of NSAIDS or colchicine
X
Peptic ulcer without H2 antagonist or proton pump inhibitor X 
acetylsalicylic acid X
Peptic ulcer X proton pump inhibitor in the highest therapeutic 
dose for more than 8 weeks X
TABLE IV - List of potentially inappropriate medications (PIM) for the elderly that should be avoided as indicated by the clinical 
diagnosis of the patient (drug interaction with disease), the dose, frequency and duration of the drug administration and drug 
association, according to the methods identified in PAHO (available at: http://regional.bvsalud.org/php/index.php), Lilacs and 
Pubmed databases, during the period between February and March 2010 (n=9) (cont.)
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UlcerX NSAIDS X X X X
Questionable efficacy
Benzodiazepines X
Drugs that act in the gastrointestinal tract with anticholinergic 
properties X
Cerebral vasodilator X
NSAIDs: nonsteroidal anti-inflammatory drugs; COPD: chronic obstructive pulmonary disease; ACEI: angiotensin-converting-
enzyme inhibitor; MAOI: monoamino oxidase inhibitor; SSRI: selective serotonin reuptake inhibitor; CNS: central nervous system.
TABLE IV - List of potentially inappropriate medications (PIM) for the elderly that should be avoided as indicated by the clinical 
diagnosis of the patient (drug interaction with disease), the dose, frequency and duration of the drug administration and drug 
association, according to the methods identified in PAHO (available at: http://regional.bvsalud.org/php/index.php), Lilacs and 
Pubmed databases, during the period between February and March 2010 (n=9) (cont.)
robustly assessed, allowing interventions to decrease 
medication prescribing errors.
Furthermore, the inclusion of safer equivalent 
therapies for the elderly in the list of Brazilian essential 
medicines may be another approach able to promote the 
safe use of drugs for the elderly, as well as to increase their 
access to less harmful medicines. This measure could have 
a great impact in developing countries, where most of the 
population is attended in public health care services, which 
commonly use RENAME to standardize their drugs.  In 
Brazil, the total coverage of the public health service is 
70% (IBGE, 2009) and approximately 20% of PIM are 
essential medicines (RENAME 2012). Although they 
meet the criteria of quality, safety, effectiveness and low 
cost for the majority of population, they are considered 
unsafe for elderly people. Therefore, the RENAME should 
make an assessment of the cost/benefit of the inclusion of 
safer alternatives for this age group, presented as a safety 
indicator of Pharmaceutical Assistance Management.
It is important to mention that there is no safer 
equivalent therapies for seven of the PIM considered 
essential medicines. In these cases, the development of 
clinical protocols clarifying the conditions of use and the 
measures required to avoid harming the health is essential. 
In addition pharmacotherapeutic follow-up may optimize 
the treatment, since it allows early recognition of negative 
clinical outcomes and may avoid therapeutic failure by 
noncompliance (Maust et al., 2013).
Finally, particular care should be taken with PIM 
that are over the counter (OTC) drugs (salicylic acid, 
ibuprofen, naproxen, belladonna alkaloids, scopolamine, 
dexchlorpheniramine, doxylamine, bisacodyl, cáscara 
sagrada, mineral oil, castor oil, ferrous sulphate, 
brompheniramine, carbinoxamine, cyproheptadine, 
chlorpheniramine, phenylephrine, carisoprodol, 
orphenadrine). This fact highlights the role of pharmacists 
in providing quality information regarding the correct 
use of drugs. Recently, the Brazilian Pharmacy Federal 
Council approved the pharmaceutical prescribing of OTC 
drugs (CFF, 2013), so that the treatment of minor disorders 
in drugstores is feasible. In this setting, the pharmacist 
should consider the risk/benefit of using a drug, the clinical 
conditions of the patient (renal or hepatic impairments, 
allergies, morbidities and comorbidities that contraindicate 
its use) and the safety of the drug to choose the best option 
for the user. Therefore, it is important aware them regarding 
the sanitary risk involving the use of PIM by elderly people.
Study limitations
The data may be underestimated because of selection 
bias, due to: 1) the search strategy in the databases; 2) data 
collection period; 3) restriction os search to; 4) articles 
selected for analysis being written in Spanish, English and 
Portuguese languages alone, and 5) 26 [12.8% (26/203)] 
manuscripts being unavailable for analysis. Therefore, 
some other criteria developed to assess the quality of drugs 
prescribed for elderly people may not have been identified 
by the methods used in this study.
CONCLUSION
The Brazilian register of essential medicines 
(RENAME) lists effective, safe and economic drugs. 
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However, approximately 25% of them are considered 
potentially inappropriate for elderly people. Therefore, 
they do not meet the safety attribute for this age group, 
most of whom are attended in public health care services 
and, in general, use polypharmacy. Thus, it is necessary 
for less noxious drugs for this population to be included 
in RENAME, in order to provide access to more effective 
treatments with less harmful potential. In this setting, the 
pharmacist can contribute to the safety assessment and 
follow-up of geriatric pharmacotherapy, mainly for those 
PIM that have no safer equivalent therapies (digoxin, 
estrogen, haloperidol, hydrochlorthiazide, ciprionate 
testosterone, nifedipine and ferrous sulphate), as well 
as  for those that are OTC drugs whose use is not exempt 
from counseling. These measures would meet the national 
policy of risk management. Furthermore, the intensive 
monitoring of medicines allows the establishment of safety 
indicators for Pharmaceutical Assistance.
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